288 related articles for article (PubMed ID: 29458047)
1. Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T; Valentovic MA; Rankin GO
Biochem Pharmacol; 2018 Jul; 153():196-204. PubMed ID: 29458047
[TBL] [Abstract][Full Text] [Related]
2. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
3. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.
Gerber JG; Rhodes RJ; Gal J
Chirality; 2004 Jan; 16(1):36-44. PubMed ID: 14628297
[TBL] [Abstract][Full Text] [Related]
4. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction.
Levran O; Peles E; Hamon S; Randesi M; Adelson M; Kreek MJ
Addict Biol; 2013 Jul; 18(4):709-16. PubMed ID: 21790905
[TBL] [Abstract][Full Text] [Related]
5. Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.
Kharasch ED; Regina KJ; Blood J; Friedel C
Anesthesiology; 2015 Nov; 123(5):1142-53. PubMed ID: 26389554
[TBL] [Abstract][Full Text] [Related]
6. Role of CYP2B6 in stereoselective human methadone metabolism.
Totah RA; Sheffels P; Roberts T; Whittington D; Thummel K; Kharasch ED
Anesthesiology; 2008 Mar; 108(3):363-74. PubMed ID: 18292673
[TBL] [Abstract][Full Text] [Related]
7. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokkar M; Gothuey I; Hämmig R; Monnat M; Hüttemann H; Baumann P; Eap CB
Clin Pharmacol Ther; 2005 Dec; 78(6):593-604. PubMed ID: 16338275
[TBL] [Abstract][Full Text] [Related]
8. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
Crettol S; Déglon JJ; Besson J; Croquette-Krokar M; Hämmig R; Gothuey I; Monnat M; Eap CB
Clin Pharmacol Ther; 2006 Dec; 80(6):668-81. PubMed ID: 17178267
[TBL] [Abstract][Full Text] [Related]
9. Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review.
Volpe DA; Xu Y; Sahajwalla CG; Younis IR; Patel V
J Pharm Sci; 2018 Dec; 107(12):2983-2991. PubMed ID: 30205091
[TBL] [Abstract][Full Text] [Related]
10. Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.
Ahmad T; Sabet S; Primerano DA; Richards-Waugh LL; Rankin GO
J Anal Toxicol; 2017 May; 41(4):325-333. PubMed ID: 28184434
[TBL] [Abstract][Full Text] [Related]
11. Enantiomeric metabolic interactions and stereoselective human methadone metabolism.
Totah RA; Allen KE; Sheffels P; Whittington D; Kharasch ED
J Pharmacol Exp Ther; 2007 Apr; 321(1):389-99. PubMed ID: 17259447
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use.
Ramli FF
Bosn J Basic Med Sci; 2021 Apr; 21(2):145-154. PubMed ID: 32841585
[TBL] [Abstract][Full Text] [Related]
13. [New psychopharmacologic studies on methadone: implications for the treatment of opiate dependency].
Eap CB
Rev Med Suisse Romande; 2000 Feb; 120(2):111-6. PubMed ID: 10748696
[TBL] [Abstract][Full Text] [Related]
14. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
15. Novel associations between
Packiasabapathy S; Aruldhas BW; Zhang P; Overholser BR; Quinney SK; Sadhasivam S
Pharmacogenomics; 2021 Jul; 22(10):591-602. PubMed ID: 34100292
[No Abstract] [Full Text] [Related]
16. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
Moody DE; Liu F; Fang WB
J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
[TBL] [Abstract][Full Text] [Related]
17. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
19. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.
Wójcikowski J; Pichard-Garcia L; Maurel P; Daniel WA
Br J Pharmacol; 2003 Apr; 138(8):1465-74. PubMed ID: 12721102
[TBL] [Abstract][Full Text] [Related]
20. Methadone: a review of drug-drug and pathophysiological interactions.
Kapur BM; Hutson JR; Chibber T; Luk A; Selby P
Crit Rev Clin Lab Sci; 2011; 48(4):171-95. PubMed ID: 22035341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
